has the potential to end COVID-19 new first-generation vaccine
EpicentRx is a private biotechnology company focused on a variety of immune in disease-induced diseases. It is headquartered in La Jolla, California. is developing issuing a nucleocapsid instead of spike protein ( spike protein) SARS-CoV-2 next generation COVID vaccine.
Expression of SARS-CoV-2 nucleocapsular protein adenovirus vaccine may be more resistant to COVID-19 variant.
Since the wave of SARS-CoV-2 variants, the actual effectiveness of COVID-19 vaccine based on spike protein has generally decreased.
Due to spike protein will frequently mutation, , and core shell does not. If can change or dissolve the three-dimensional structure of the virus capsid, RNA will be released by , and the virus will not survive.
EpicentRx plan to cooperate with other partners to include the next generation of COVID-19 candidate vaccine based on nucleocapsid into clinical trials.
After discussed with pharmaceutical companies and some government agencies, has prepared a batch of GMP standard manufacturing samples of .
nucleocapsid is a relatively large protein with multiple Th cell epitope ( immune system recognizes part of antigen ) . vaccine based on nucleocapsid can also activate Th cells, thereby producing a long-term immune response of .
in early January, the International Journal of Infectious Diseases published an article on the need for the next generation of COVID-19 candidate vaccine based on the nuclear . EpicentRx Company members also participated in the work. (EpicentRx Company mainly focuses on cancer vaccines and has rich experience in providing vaccines for immunosuppressed cancer patients. )
Dr. Tony Reid
TonyReid pointed out that early description of immunosuppressed patients infected with COVID-19 found that their bodies are the vector . These patients produce the immune response of polyclonal antibody, but their Th cells have not responded strongly, and may develop viremia. Therefore, drug resistance mutation body , and this situation of has led to the decrease in the effectiveness of the new coronavirus vaccine and antibodies.
Pfizer , Modner These pharmaceutical companies focus on spike protein is that can understand , , because it is effective in targeting spike protein, is still very effective . However, since the spike protein often mutates, it is still challenging to develop a vaccine against the latest circulating variants in .
New crown ravages During the period when , the development of the vaccine based on nucleocapsid is unprecedented , This is a new technology , and no one knows whether is effective . When the third phase of study on vaccines shows that the efficacy of vaccines exceeds 90% , many people believe that the new coronavirus will end .
But now, the virus is still spreading infection around the world. Reid means that uses nucleocapsid to enhance vaccine is the imperative , because many of the problems we see now are long-term organ toxicity. Therefore, the Th cell reaction that can eradicate the virus from infected cells will be the main role of nucleocapsid technology .
EpicentRx also conducted a phase one study on the treatment of cancer. At the heart of this study is AdAPT-001, which carries a gene that can capture or neutralize a protein called transforming growth factor β (TGF-β).
